Clinical Trial Detail

NCT ID NCT03213678
Title PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Ewing sarcoma

medulloblastoma

non-Hodgkin lymphoma

Advanced Solid Tumor

hepatoblastoma

rhabdomyosarcoma

malignant glioma

neuroblastoma

pediatric osteosarcoma

pediatric ependymoma

Therapies

LY3023414

Age Groups: adult child

Additional content available in CKB BOOST